[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351214-105":59,"doc-detail-351214-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","first-in-human-phase-1-study-of-ro7119929-an-oral-tlr7-agonist-prodrug-in-patients-with-advanced-primary-or-metastatic-liver-cancers","First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers","","First-in-human phase 1 study evaluates the orally available TLR7 agonist prodrug RO7119929 for safety, pharmacokinetics, preliminary antitumor activity, and proof-of-mechanism in patients with liver cancer. RO7119929 is converted mainly in the liver, aiming to reprogram the local immune microenvironment. The open-label design includes dose-escalation and expansion with flat dose or step-up dosing schedules across advanced or metastatic disease.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/first-in-human-phase-1-study-of-ro7119929-an-oral-tlr7-agonist-prodrug-in-patients-with-advanced-primary-or-metastatic-liver-cancers/351214/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/first-in-human-phase-1-study-of-ro7119929-an-oral-tlr7-agonist-prodrug-in-patients-with-advanced-primary-or-metastatic-liver-cancers/351214.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is RO7119929 and what is its proposed mechanism in liver cancer?","Question",{"text":112,"@type":113},"RO7119929 is an oral TLR7 agonist prodrug converted predominantly in the liver. It is hypothesized to reprogram the local immune microenvironment through cytokine induction and related effects on effector T cells toward the tumor environment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the phase 1 study designed and what dosing schedules were used?",{"text":117,"@type":113},"The study was an open-label, first-in-human dose-escalation and expansion trial. Patients received RO7119929 weekly in 3-week cycles using either a flat dose schedule or a step-up dose schedule.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key safety findings, particularly regarding cytokine release syndrome?",{"text":121,"@type":113},"Treatment-related adverse events occurred in most treated patients, with cytokine release syndrome (CRS) being the most common. CRS showed dose-dependent incidence and severity and acted as a dose-limiting safety risk.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351214,1790197364,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Open access Original research  \nFirst-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers  \nChanghoon Yoo,1 Carles Fabregat-Franco,2 Chia-Chi Lin  ,3 Camilla Qvortrup,4 Do-Youn Oh,5,6 Thomas Yau,7 Hyung-Don Kim,1 Florian Castet,2  \nMariano Ponz Sarvise  ,8 Chiun Hsu,3 Kristoffer Staal Rohrberg  ,9  \nFelix Sebastian Lichtenegger,10 Izolda Franjkovic  ,11 Nicole A Kratochwil,12 Juliana Bessa,12 Eva Rossmann,12 Petra C Schwalie  ,13 Natascha Rieder,10 Thomas Pöschinger  ,14 Christina Godfried Sie,12 Steffen Dettling,10 Ramona Schlenker,12 Tianyi Jiang,15 Congqi Dai,15 Hongying Yun,15 Elia Hall,12 Audrey Yeo Te-Ying,12 Sabine Hoves,10 Michael A Cannarile,10 Christina Schiff,12 Bruno Sangro  16  \nTo cite: Yoo C, FabregatFranco C, Lin C-C, et al.  \nFirst-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers. Journal for ImmunoTherapy of Cancer 2026;14:e012783 . doi:10 . 1136/ jitc-2025-012783  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-012783](jitc-2025-012783)) .  \nAccepted 09 February 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Bruno Sangro; [bsangro@unav.es](bsangro@unav.es)  \nABSTRACT  \nBackground The orally available toll-like receptor 7 (TLR7) agonist prodrug RO7119929 is converted to active drug predominantly in the liver, where it is hypothesized toreprogram the local immune microenvironment. We aimed to explore the safety, pharmacokinetics (PK), and preliminary antitumor activity and obtain the proof-of-mechanism for RO7119929 in patients with liver cancer.  \nMethods RO7119929 was investigated in mouse tumors and liver tissue from cynomolgus monkeys. In the first-in-human, open-label, dose-escalation and expansion study, patients with histologically confirmed advanced or metastatic primary liver cancers or solid tumors with predominant liver involvement received RO7119929 weekly in 3-week cycles either on a flatdose (FD) or step-up dose (SUD) schedule.  \nResults Preclinical results demonstrated antitumor activity and the proinflammatory proof-of-mechanism in mouse liver tumors and cynomolgus monkey liver tissue. The subsequent first-in-human study enrolled 27patients in five FD doseescalation cohorts, 18patients in a FD dose-expansion cohort, and 9patients in two SUD dose-escalation cohorts. The most common primary tumor type at study entry was hepatocellular carcinoma (HCC) (31%). PK data showed fast conversion of RO7119929 to the active TLR7 agonist. Treatment-related adverse events (TRAEs) were observed in 50 (91%) patients across all treated patients; the most commonly reported TRAE was cytokine release syndrome (CRS) in 48 (81%) patients. CRS was also identified as a dose-limiting safety risk and had a dose-dependent incidence and severity. Grade 3 CRS  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ The clinical use of toll-like receptor 7 (TLR7) agonists for the treatment of cancer is hampered due to systemic immune activation leading to dose-limiting toxicities.\u003Cbr>⇒ The TLR7 agonist prodrug RO7119929 is converted to its active drug predominantly in the liver (1), and is hypothesized to reprogram the local immune microenvironment by cytokine induction (2) and secondary attraction of effector T cells to the tumor environment (3) .\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ Treatment with single-agent RO7119929 induced local inflammation via myeloid cells both in animal models and patients with advanced or metastatic primary liver cancers or solid tumors with predominant liver involvement.\u003Cbr>⇒ Step-up dosing reduced the risk of cytokine re","cbCaijGZxjZBVZmb","https://ap.wps.com/l/cbCaijGZxjZBVZmb","pdf",6011117,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Rationale for immune activation with TLR7 agonists","[{\"question\":\"What is RO7119929 and what is its proposed mechanism in liver cancer?\",\"answer\":\"RO7119929 is an oral TLR7 agonist prodrug converted predominantly in the liver. It is hypothesized to reprogram the local immune microenvironment through cytokine induction and related effects on effector T cells toward the tumor environment.\"},{\"question\":\"How was the phase 1 study designed and what dosing schedules were used?\",\"answer\":\"The study was an open-label, first-in-human dose-escalation and expansion trial. Patients received RO7119929 weekly in 3-week cycles using either a flat dose schedule or a step-up dose schedule.\"},{\"question\":\"What were the key safety findings, particularly regarding cytokine release syndrome?\",\"answer\":\"Treatment-related adverse events occurred in most treated patients, with cytokine release syndrome (CRS) being the most common. CRS showed dose-dependent incidence and severity and acted as a dose-limiting safety risk.\"}]","First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers | PDF",1790093080,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/852d4fce5f256786657b7a948ac7a281.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/939d5ae9d04b2ad0aff787349527ef03.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/185c30111e5576f5187c26a2ae54b12f.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83dc58d62cc8f39a8624d221e4f75704.webp",980,1306]